Roth MKM Maintains Buy on Panbela Therapeutics, Adjusts Price Target To $25

Moomoo 24/7 ·  Feb 5 14:12

Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (NASDAQ:PBLA) with a Buy, adjusts target to $25 from $500.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment